ORGO Q2 2022 Earnings — Organogenesis Holdings Inc. Revenue & Financial Results | Market Cap Arena

ORGOOrganogenesis Holdings Inc.

$355M

Q2 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$121M-1.5% YoY

Gross Profit

$95M78.0% margin

Operating Income

$12M9.8% margin

Net Income

$9M7.2% margin

EPS (Diluted)

$0.07

QoQ Revenue Growth

+25.0%

Cash Flow

Operating Cash Flow

$10M

Free Cash Flow

$4M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$456M

Total Liabilities

$202M

Stockholders' Equity

$254M

Cash & Equivalents

$112M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$121M	$123M	-1.5%
Gross Profit	$95M	$93M	+1.6%
Operating Income	$12M	$24M	-49.4%
Net Income	$9M	$21M	-57.7%

Revenue Segments

Advanced Wound care

$114M94%

Surgical and Sports Medicine

$8M6%